Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy

L. Qin, B Douglas Smith, H. L. Tsai, N. K. Yaghi, P. H. Neela, M. Moake, Jie Fu, Y. L. Kasamon, G. T. Prince, M. Goswami, Gary Rosner, H. I. Levitsky, Christopher Hourigan

Research output: Contribution to journalArticle

Abstract

The ability to target myeloid leukemia with immunotherapy would represent a significant therapeutic advance. We report here immunological analysis of clinical trials of primary and secondary vaccination with K562/GM-CSF immunotherapy in adult chronic phase chronic myeloid leukemia patients (CML-CP) with suboptimal responses to imatinib mesylate. Using serological analysis of recombinant cDNA expression libraries of K562 with autologous vaccinated patient serum, we have identified 12 novel chronic myeloid leukemia-associated antigens (LAAs). We show that clinical responses following K562/GM-CSF vaccination are associated with induction of high-titer antibody responses to multiple LAAs. We observe markedly discordant patterns of baseline and induced antibody responses in these identically vaccinated patients. No single antigen was recognized in all responses to vaccination. We demonstrate that an additional 'booster' vaccination series can be given safely to those with inadequate responses to initial vaccination, and is associated with more frequent induction of IgG responses to antigens overexpressed in K562 vaccine compared with primary CML-CP. Finally, those with induced immune responses to the same LAAs often shared HLA subtypes and patients with clinical responses following vaccination recognized a partially shared but non-identical spectrum of antigens; both findings have potentially significant implications for cancer vaccine immunotherapy.

Original languageEnglish (US)
Article numbere145
JournalBlood Cancer Journal
Volume3
Issue number9
DOIs
StatePublished - Sep 2013

Fingerprint

Immunotherapy
Leukemia
Vaccination
Immunoglobulin G
Antigens
Antibodies
Granulocyte-Macrophage Colony-Stimulating Factor
Antibody Formation
Leukemia, Myeloid, Chronic Phase
Cancer Vaccines
Myeloid Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Gene Library
Vaccines
Clinical Trials
Serum

Keywords

  • Cancer vaccines
  • Chronic myeloid
  • Immunotherapy
  • K562 cells
  • Leukemia

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy. / Qin, L.; Smith, B Douglas; Tsai, H. L.; Yaghi, N. K.; Neela, P. H.; Moake, M.; Fu, Jie; Kasamon, Y. L.; Prince, G. T.; Goswami, M.; Rosner, Gary; Levitsky, H. I.; Hourigan, Christopher.

In: Blood Cancer Journal, Vol. 3, No. 9, e145, 09.2013.

Research output: Contribution to journalArticle

Qin, L. ; Smith, B Douglas ; Tsai, H. L. ; Yaghi, N. K. ; Neela, P. H. ; Moake, M. ; Fu, Jie ; Kasamon, Y. L. ; Prince, G. T. ; Goswami, M. ; Rosner, Gary ; Levitsky, H. I. ; Hourigan, Christopher. / Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy. In: Blood Cancer Journal. 2013 ; Vol. 3, No. 9.
@article{477b47a5e28a4054b550e880d363df8e,
title = "Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy",
abstract = "The ability to target myeloid leukemia with immunotherapy would represent a significant therapeutic advance. We report here immunological analysis of clinical trials of primary and secondary vaccination with K562/GM-CSF immunotherapy in adult chronic phase chronic myeloid leukemia patients (CML-CP) with suboptimal responses to imatinib mesylate. Using serological analysis of recombinant cDNA expression libraries of K562 with autologous vaccinated patient serum, we have identified 12 novel chronic myeloid leukemia-associated antigens (LAAs). We show that clinical responses following K562/GM-CSF vaccination are associated with induction of high-titer antibody responses to multiple LAAs. We observe markedly discordant patterns of baseline and induced antibody responses in these identically vaccinated patients. No single antigen was recognized in all responses to vaccination. We demonstrate that an additional 'booster' vaccination series can be given safely to those with inadequate responses to initial vaccination, and is associated with more frequent induction of IgG responses to antigens overexpressed in K562 vaccine compared with primary CML-CP. Finally, those with induced immune responses to the same LAAs often shared HLA subtypes and patients with clinical responses following vaccination recognized a partially shared but non-identical spectrum of antigens; both findings have potentially significant implications for cancer vaccine immunotherapy.",
keywords = "Cancer vaccines, Chronic myeloid, Immunotherapy, K562 cells, Leukemia",
author = "L. Qin and Smith, {B Douglas} and Tsai, {H. L.} and Yaghi, {N. K.} and Neela, {P. H.} and M. Moake and Jie Fu and Kasamon, {Y. L.} and Prince, {G. T.} and M. Goswami and Gary Rosner and Levitsky, {H. I.} and Christopher Hourigan",
year = "2013",
month = "9",
doi = "10.1038/bcj.2013.44",
language = "English (US)",
volume = "3",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy

AU - Qin, L.

AU - Smith, B Douglas

AU - Tsai, H. L.

AU - Yaghi, N. K.

AU - Neela, P. H.

AU - Moake, M.

AU - Fu, Jie

AU - Kasamon, Y. L.

AU - Prince, G. T.

AU - Goswami, M.

AU - Rosner, Gary

AU - Levitsky, H. I.

AU - Hourigan, Christopher

PY - 2013/9

Y1 - 2013/9

N2 - The ability to target myeloid leukemia with immunotherapy would represent a significant therapeutic advance. We report here immunological analysis of clinical trials of primary and secondary vaccination with K562/GM-CSF immunotherapy in adult chronic phase chronic myeloid leukemia patients (CML-CP) with suboptimal responses to imatinib mesylate. Using serological analysis of recombinant cDNA expression libraries of K562 with autologous vaccinated patient serum, we have identified 12 novel chronic myeloid leukemia-associated antigens (LAAs). We show that clinical responses following K562/GM-CSF vaccination are associated with induction of high-titer antibody responses to multiple LAAs. We observe markedly discordant patterns of baseline and induced antibody responses in these identically vaccinated patients. No single antigen was recognized in all responses to vaccination. We demonstrate that an additional 'booster' vaccination series can be given safely to those with inadequate responses to initial vaccination, and is associated with more frequent induction of IgG responses to antigens overexpressed in K562 vaccine compared with primary CML-CP. Finally, those with induced immune responses to the same LAAs often shared HLA subtypes and patients with clinical responses following vaccination recognized a partially shared but non-identical spectrum of antigens; both findings have potentially significant implications for cancer vaccine immunotherapy.

AB - The ability to target myeloid leukemia with immunotherapy would represent a significant therapeutic advance. We report here immunological analysis of clinical trials of primary and secondary vaccination with K562/GM-CSF immunotherapy in adult chronic phase chronic myeloid leukemia patients (CML-CP) with suboptimal responses to imatinib mesylate. Using serological analysis of recombinant cDNA expression libraries of K562 with autologous vaccinated patient serum, we have identified 12 novel chronic myeloid leukemia-associated antigens (LAAs). We show that clinical responses following K562/GM-CSF vaccination are associated with induction of high-titer antibody responses to multiple LAAs. We observe markedly discordant patterns of baseline and induced antibody responses in these identically vaccinated patients. No single antigen was recognized in all responses to vaccination. We demonstrate that an additional 'booster' vaccination series can be given safely to those with inadequate responses to initial vaccination, and is associated with more frequent induction of IgG responses to antigens overexpressed in K562 vaccine compared with primary CML-CP. Finally, those with induced immune responses to the same LAAs often shared HLA subtypes and patients with clinical responses following vaccination recognized a partially shared but non-identical spectrum of antigens; both findings have potentially significant implications for cancer vaccine immunotherapy.

KW - Cancer vaccines

KW - Chronic myeloid

KW - Immunotherapy

KW - K562 cells

KW - Leukemia

UR - http://www.scopus.com/inward/record.url?scp=84885336017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885336017&partnerID=8YFLogxK

U2 - 10.1038/bcj.2013.44

DO - 10.1038/bcj.2013.44

M3 - Article

C2 - 24013666

AN - SCOPUS:84885336017

VL - 3

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 9

M1 - e145

ER -